Navigation Links
Groupe Athena, Inc. Provides Guidance on Current Orders
Date:8/15/2011

MUMBAI, India, Aug. 15, 2011 /PRNewswire/ -- Groupe Athena, Inc. (Pink Sheets: GATA) made the following announcement:

The guidance contained below represents forecasts, which indicate possible outcomes and are provided to assist investors with the development of earnings estimates. While Groupe Athena, Inc. believes that these forecasts represent the best estimate of management as to future events, actual events may differ from these forecasts, and such differences could be material. These forecasts are subject to risks identified under "Safe Harbor Statement" below.

Groupe Athena, Inc. announced today they have approximately $60 million in customer orders that they are currently processing, and they are hopeful that this number will increase in the near term.  Based on the orders in hand the company expects to be able to convert at least two thirds or approximately $40 million into revenue during the current fiscal year.

The company also stated that due to the recent capital investments in equipment and facilities which has increased their ability to perform more services in-house, they will to be able to increase net profit margins on future revenues by 1.5-2%.    

The company is still committed to funding all capital expenditures entirely from internal cash accruals without any further dilution or debt increases.

As was previously stated, the Indian pharmaceutical industry is increasingly focusing on exports to the United States and GATA is well positioned to help them get their products approved by the FDA for sales in the US. All of these are potential clients and the Company believes it has an advantage over competitors due to the facilities based in India, and their ability to deliver quick feedback to clients that could result in expedited order generation. With recent additions to equipment, the company will continue to take on additional contracts and continue to anticipate further growth.

About Groupe Athena, Inc.

Groupe Athena, Inc. was incorporated in June 2008 and began operations on July 1 of that year. The company is a research and testing organization and helps various pharmaceutical and medical products and devices companies in India and Southeast Asia to get regulatory approvals and facilitate exports of their products to the United States. The Company accomplishes this by assisting clients from concept through development, providing consultation on regulatory requirements, filings and processes.

The company has a research and marketing facility in India that currently employs 15 consultants and marketing personnel and is working towards aggressively expanding its presence in the Indian pharmaceutical industry. The Company's web address is www.groupeathena.com.

For more information contact:
Paul Cornell
Corporate Shareholder Relations, Inc.
pcornell@totalpublicrelations.com

Safe Harbor Statement

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate", "project", "intend", "forecast", "anticipate", "plan", "planning", "expect", "believe", "will likely", "should", "could", "would", "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions -- activities of competitors and the presence of new or additional competition and conditions of equity markets.


'/>"/>
SOURCE Groupe Athena, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Groupe Athena, Inc. Profits Soar on Record Revenues
2. NeoStem Provides Update on Amorcyte Clinical Progress and Reports Results for Second Quarter
3. Allergy Technologies LLC Provides Over $100,000 in a Research Grant to The Ohio State University for the Study of Bed Bugs
4. Millennium Surgical Provides Services and Support to CURE Internationals Zambian Surgical Program
5. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
6. HASCO Medical Chairman Provides $2 Million in Capital and a Personal Guarantee on Additional $2 Million Promissory Note
7. Generex Provides Corporate Update
8. Cardium Provides Update on Excellagen 510(K) Registration and Commercialization Plans
9. Bayer HealthCare Provides Nearly $2.5 Million to Advance Hemophilia Research and Patient Care
10. Abbotts HIV Combo Test Detects Infections Earlier, Provides Valuable Information to Help Prevent Further HIV Transmission and May Save Treatment Costs
11. Enhanced POP 2.0 Provides Custom Insight Into the Physicians Mindset at the Point of Promotion and Prescribing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Ky. , Feb. 12, 2016 /PRNewswire/ ... has completed a $47.1 million Series D ... Cormorant Asset Management, Hillhouse Capital Group and ... Morningside Venture Investments, AJU IB Investment, and ... be used to further advance clinical trials ...
(Date:2/11/2016)... The primary goal of this research is ... the usage of liquid biopsy. Key information the survey ... Timeframe of liquid biopsy adoption amidst future users - ... type - Sample inflow to conduct liquid biopsy tests ... and so on. - Correlation analysis of sample type ...
(Date:2/11/2016)... Feb. 11, 2016  Kindred Biosciences, Inc. (NASDAQ: ... improving the lives of pets, today announced the submission ... New Animal Drug Application (NADA) for Zimeta™ (dipyrone injection, ... (KB0120) of Zimeta for the control of pyrexia (fever) ... --> --> The Chemistry, ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Erlanger Agency has announced a new ... area. The latest campaign focuses on the fight against breast cancer, fundraising for a ... accepted here . , Carmen is a loving single mother of two boys ...
(Date:2/12/2016)... San Ramon, CA (PRWEB) , ... February 12, 2016 , ... ... tissue donation in northern California and Nevada, announced a partnership with San Ramon Regional ... be transferred to the hospital’s facilities as a way to accommodate a more certain ...
(Date:2/12/2016)... FL (PRWEB) , ... February 12, 2016 , ... For ... Dental hygienist Suzan Sweeney, RDH, and dental assistant Terrell Moore shortly before 7 a.m. ... joined dozens of dental professionals, donating their time and skills to help hundreds of ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... “Revolutionizing Cancer Care.” , The print component of “Revolutionizing Cancer Care” ... Pittsburgh/Cleveland, New York, Washington DC/Baltimore, and Seattle, with a circulation of approximately 250,000 ...
(Date:2/12/2016)... ... 12, 2016 , ... Atlantic Information Services, Inc. (AIS) is ... an upcoming Feb. 24 webinar that will discuss ways health plans and PBMs ... as the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat ...
Breaking Medicine News(10 mins):